The dysregulation of fibroblast growth factor (FGF) signaling has been implicated in
tumorigenesis, tumor progression, angiogenesis, and chemoresistance. The small-molecule …

Abstract A series of 2-oxo-3, 4-dihydropyrimido [4, 5-d]-pyrimidinyl derivatives were
designed and synthesized as new irreversible inhibitors of the FGFR family. One of the most …

Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) inhibitor. It has been
recently approved on April 2019 by FDA for patients with urothelial carcinoma that has …

Background: Angiogenesis is a mechanism, which tumors use to recruit oxygen and
nutrients in order to maintain growth. The vascular endothelial growth factor family is the …

Fibroblast growth factor receptor (FGFR) is a promising anticancer target. Currently, most
FGFR inhibitors lack sufficient selectivity and have nonnegligible activity against kinase …

More than ten thousand peer‐reviewed studies have assessed the role of fibroblast growth
factors (FGFs) and their receptors (FGFRs) in cancer, but few patients have yet benefited …

This article describes in vivo biotransformation and disposition of erdafitinib following single
oral dose of 3H-erdafitinib and 14C-erdafitinib to intact and bile duct-cannulated (BC) rats (4 …

Aberrant over-expressions of FGF9 in gastric cancer (GC) and its high-affinity receptor
FGFR3c in bladder cancer (BC) provide possibilities for the treatment of GC and BC via …

Pigmentation processes provide a traceable and relevant trait for understanding key issues
in evolutionary biology such as adaptation, speciation and the maintenance of balanced …

Background: Despite recent advances in the understanding of the molecular landscape of
biliary tract cancer (BTC), advanced disease continues to carry a poor prognosis, and the …